Federated Hermes Inc. Takes $21.26 Million Position in Palvella Therapeutics, Inc. $PVLA

Federated Hermes Inc. acquired a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 339,047 shares of the company’s stock, valued at approximately $21,255,000. Federated Hermes Inc. owned 3.07% of Palvella Therapeutics as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of PVLA. Frazier Life Sciences Management L.P. lifted its stake in Palvella Therapeutics by 4.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after buying an additional 32,388 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Palvella Therapeutics during the first quarter worth $7,553,000. Geode Capital Management LLC lifted its position in Palvella Therapeutics by 84.7% in the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after acquiring an additional 79,787 shares in the last quarter. Marshall Wace LLP lifted its position in Palvella Therapeutics by 61.7% in the 2nd quarter. Marshall Wace LLP now owns 49,077 shares of the company’s stock valued at $1,106,000 after acquiring an additional 18,732 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in Palvella Therapeutics in the 1st quarter worth $533,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 12,906 shares of company stock valued at $1,205,980. Company insiders own 20.50% of the company’s stock.

Palvella Therapeutics Stock Down 6.4%

NASDAQ:PVLA opened at $76.69 on Friday. Palvella Therapeutics, Inc. has a twelve month low of $12.60 and a twelve month high of $114.69. The firm has a market capitalization of $908.01 million, a price-to-earnings ratio of -29.16 and a beta of -0.16. The stock’s 50 day moving average price is $96.59 and its two-hundred day moving average price is $72.30.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PVLA. Canaccord Genuity Group boosted their price target on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. UBS Group restated a “buy” rating and issued a $143.00 target price on shares of Palvella Therapeutics in a research note on Monday, December 15th. Cantor Fitzgerald raised their price target on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Finally, BTIG Research reissued a “buy” rating and issued a $192.00 price objective on shares of Palvella Therapeutics in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $158.69.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.